Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026)

Vertex Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $961.6 million for Q1 2026.

• In Q1 2026, Research & Development fell 1.85% year-over-year to $961.6 million; the TTM figure through Mar 2026 stood at $3.9 billion (up 1.85% YoY), while the FY2025 annual figure was $3.9 billion, up 7.69% from the prior year.
• Research & Development for Q1 2026 stood at $961.6 million, down from $973.7 million in the prior quarter.
• The five-year high for Research & Development was $998.7 million in Q4 2024, with the low at $600.1 million in Q2 2022.
• The 5-year median for Research & Development is $824.6 million (2023), against an average of $835.6 million.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 38.12% in 2022, then retreated 2.5% in 2025.
• Vertex Pharmaceuticals' Research & Development stood at $694.1 million in 2022, then advanced by 18.8% to $824.6 million in 2023, then rose by 21.11% to $998.7 million in 2024, then slipped by 2.5% to $973.7 million in 2025, then dropped by 1.24% to $961.6 million in 2026.
• Business Quant data shows VRTX's Research & Development at $961.6 million in Q1 2026, $973.7 million in Q4 2025, and $977.7 million in Q3 2025.